(Boursier.com) — Medesis Pharma filed a new European patent application on the optimization of its Aonys microemulsion technology platform to increase bioavailability and improve patient compliance.
This new patent guarantees industrial protection until 2043 for all drug applications of the Aonys technology, and strengthens the assets of Medesis Pharma, which holds 72 patents spread over 11 patent families.
Remember that the Aonys microemulsion, developed since the creation of Medesis Pharma, consists of reverse micelles with a specific composition which, after having been deposited on the oral mucosa, allows absorption in the mucosa, the structuring of HDL lipoproteins ensuring their transport plasmatic then the delivery of the active principles directly inside all the cells of the organism.
©2023 Boursier.com